Greater integration is to take place between the US and UK following an expansion says Cresset, a provider of integrated in-silico solutions for drug discovery.
On March 7, Celadon Pharmaceuticals plc, a leading UK-based pharmaceutical company specializing in cannabis-based medicines, unveiled promising findings from an early economic analysis of its chronic pain clinical trial, dubbed CANPAIN.
Patients in the US with epidermal growth factor receptor mutated (EGFRm) advanced lung cancer can now receive an important new treatment option delaying disease progression by nearly nine additional months.
Biogen Inc. has taken a step closer to bringing its ‘groundbreaking treatment’ to patients with a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder.
A company building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (pathway) has announced a further extension to its series B financing round.
Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise.
An alliance between KBI Biopharma Inc., and Argonaut Manufacturing Services Inc., has been formed so biopharma clients can receive end-to-end drug substance and drug product manufacturing solutions.
The pharmaceutical industry in 2023 has seen many investments, partnerships, acquisitions and more. As the year ends, industry leaders give the biggest trends to look for in 2024, with artificial intelligence being a hot topic.
The US contract development and manufacturing organization (CDMO) Agno Pharma has taken over compatriot firm Lubrizol Particle Sciences to increase its drug product formulation offerings.
A portfolio company created and incubated by Apple Tree Partners (ATP) has raised $52 million in series A funding to enable it to rapidly discover novel small molecule therapeutics.
A treatment option to reduce the number and intensity of hot flashes and night sweats associated with menopause has been approved by the European Commission (EC).
Symbiosis Pharmaceutical Services can now test small molecule, biological and advanced therapeutical medicinal products (ATMP) following a £1 million investment.
From its origins in ancient military time where the Romans and Greeks used logistics and distribution channels to supply their armies, to today's challenges with the supply chain for pharma ingredients, we enjoyed putting some questions to Univar...
Eli Lilly has invested in its manufacturing capacity once more and has announced plans to build a $2.5 billion high-tech manufacturing site in Germany.
Using a combination of pre-existing HIV drugs, a medicine for HIV-negative people taken before sex has reduced the chances of getting the virus by 86%.
Volunteers with conditions including depression, alcohol use disorder, and anorexia are being sought by Clerkenwell Health, to join its seminal clinical trials.
It is five years this month since a ground-breaking change in UK healthcare history happened – with doctors being able to prescribe cannabis-based medicines for the first time.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).
Integrated drug discovery contract research organization (CRO) Sygnature Discovery has invested £3.75 million in an Azenta compound management storage system that can also provide customer libraries.
It was announced today (October 31), that the US Food and Drug Administration (FDA) has granted permission to proceed with clinical investigations of small molecule treatment, roginolisib.
IFF’s Pharma Solutions division is poised to introduce new products and investments at this year's CPHI being held in Barcelona. OSP was lucky enough to catch up with them before the event starting next week.
Provider of pharmaceutical and nutraceutical ingredients, Roquette, is excited to unveil its extensive range of excipients for moisture protection at CPHI Barcelona next week.
Bioiberica says the excitement for this year’s CPHI has been ‘taken up a notch’ as the company looks forward to welcoming both old and new customers to its hometown, Barcelona.
The unique glutamatergic mechanism of action in Newron Pharmaceuticals’ investigational new drug can potentially produce a long-lasting antipsychotic response in patients with TRS, and the benefits will accrue over time.
Small molecule drug, Tagrisso (Osimertinib) taken alongside chemotherapy has showed a strong improvement in progression-free survival for patients with EGFR (epidermal growth factor receptor)-mutated advanced lung cancer, a phase 3 study has revealed.
Results from a multinational trial of trifluridine/tipracil, known as Lonsurf, with or without bevacizumab in refractory metastatic colorectal cancer (mCRC) have resulted in statistically significantly and clinically meaningful improvements.
Scorpion Therapeutics, a clinical-stage oncology company, has announced that the first patient has been dosed in a phase 1/2 clinical trial of STX-478, its treatment for breast cancer and other solid tumors.
Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).
A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).
Symptom improvements have been hailed as ‘very compelling’ after results from a phase 1 study into a combination of drugs to treat myelofibrosis prove positive.
Dutch biopharmaceutical company, Pharming Group PV, has sent its first commercial shipments of a drug to treat a rare, primary immunodeficiency, to the US.